Opus Genetics Operating Expenses Growth & History (IRD)
Opus Genetics's operating expenses was $52.8M for fiscal 2025.
View full Opus Genetics company overviewOpus Genetics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $52.8M | −$20.3M | −27.74% |
| 2024 | 2024-12-31 | $73.1M | $43.5M | +146.74% |
| 2023 | 2023-12-31 | $29.6M | $8.0M | +36.94% |
| 2022 | 2022-12-31 | $21.6M | −$1.7M | −7.17% |
| 2021 | 2021-12-31 | $23.3M | $3.3M | +16.66% |
| 2020 | 2020-12-31 | $20.0M | $15.8M | +376.22% |
| 2019 | 2019-12-31 | $4.2M | −$16.3M | −79.58% |
| 2018 | 2018-12-31 | $20.5M | $3.2M | +18.34% |
| 2017 | 2017-12-31 | $17.4M | $941,332 | +5.74% |
| 2016 | 2016-12-31 | $16.4M | −$1.9M | −10.13% |
| 2015 | 2015-12-31 | $18.3M | $5.0M | +37.64% |
| 2014 | 2014-12-31 | $13.3M | $5.3M | +66.31% |
| 2013 | 2013-12-31 | $8.0M | $1.4M | +21.27% |
| 2012 | 2012-12-31 | $6.6M | −$9.6M | −59.21% |
| 2011 | 2011-12-31 | $16.1M | $5.8M | +56.52% |
| 2010 | 2010-12-31 | $10.3M | $3.8M | +59.39% |
| 2009 | 2009-12-31 | $6.5M | — | — |
Opus Genetics quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $17.2M | $5.4M | +46.21% |
| Q1 2026 | 2026-03-31 | $16.5M | $2.2M | +15.54% |
| Q4 2025 | 2025-12-31 | $15.3M | −$27.0M | −63.81% |
| Q3 2025 | 2025-09-30 | $11.4M | −$486,000 | −4.09% |
| Q2 2025 | 2025-06-30 | $11.8M | $2.3M | +24.87% |
| Q1 2025 | 2025-03-31 | $14.3M | $4.9M | +51.81% |
| Q4 2024 | 2024-12-31 | $42.3M | $35.2M | +494.54% |
| Q3 2024 | 2024-09-30 | $11.9M | $6.3M | +114.02% |
| Q2 2024 | 2024-06-30 | $9.4M | $377,000 | +4.16% |
| Q1 2024 | 2024-03-31 | $9.4M | $1.5M | +19.53% |
| Q4 2023 | 2023-12-31 | $7.1M | $1.5M | +26.24% |
| Q3 2023 | 2023-09-30 | $5.5M | $1.0M | +22.28% |
| Q2 2023 | 2023-06-30 | $9.1M | $4.1M | +83.54% |
| Q1 2023 | 2023-03-31 | $7.9M | $1.4M | +21.08% |
| Q4 2022 | 2022-12-31 | $5.6M | −$510,000 | −8.29% |
| Q3 2022 | 2022-09-30 | $4.5M | −$183,000 | −3.88% |
| Q2 2022 | 2022-06-30 | $4.9M | −$2.3M | −31.77% |
| Q1 2022 | 2022-03-31 | $6.5M | $1.3M | +25.49% |
| Q4 2021 | 2021-12-31 | $6.2M | −$7.9M | −56.14% |
| Q3 2021 | 2021-09-30 | $4.7M | $2.8M | +142.35% |
| Q2 2021 | 2021-06-30 | $7.2M | $6.0M | +473.45% |
| Q1 2021 | 2021-03-31 | $5.2M | $2.5M | +89.62% |
| Q4 2020 | 2020-12-31 | $14.0M | — | — |
| Q3 2020 | 2020-09-30 | $1.9M | −$332,624 | −14.58% |
| Q2 2020 | 2020-06-30 | $1.3M | −$1.7M | −57.77% |
| Q1 2020 | 2020-03-31 | $2.7M | −$1.2M | −30.54% |
| Q3 2019 | 2019-09-30 | $2.3M | −$2.4M | −51.31% |
| Q2 2019 | 2019-06-30 | $3.0M | −$2.0M | −40.25% |
| Q1 2019 | 2019-03-31 | $3.9M | −$1.9M | −33.10% |
| Q4 2018 | 2018-12-31 | $5.0M | $68,241 | +1.39% |
| Q3 2018 | 2018-09-30 | $4.7M | $464,585 | +11.01% |
| Q2 2018 | 2018-06-30 | $5.0M | $717,516 | +16.75% |
| Q1 2018 | 2018-03-31 | $5.9M | $1.9M | +48.89% |
| Q4 2017 | 2017-12-31 | $4.9M | $979,182 | +24.99% |
| Q3 2017 | 2017-09-30 | $4.2M | $501,747 | +13.50% |
| Q2 2017 | 2017-06-30 | $4.3M | $371,143 | +9.49% |
| Q1 2017 | 2017-03-31 | $4.0M | −$910,740 | −18.72% |
| Q4 2016 | 2016-12-31 | $3.9M | −$448,186 | −10.26% |
| Q3 2016 | 2016-09-30 | $3.7M | −$940,980 | −20.20% |
| Q2 2016 | 2016-06-30 | $3.9M | −$907,158 | −18.82% |
| Q1 2016 | 2016-03-31 | $4.9M | $446,273 | +10.10% |
| Q4 2015 | 2015-12-31 | $4.4M | $514,740 | +13.36% |
| Q3 2015 | 2015-09-30 | $4.7M | $1.5M | +48.28% |
| Q2 2015 | 2015-06-30 | $4.8M | $1.3M | +37.36% |
| Q1 2015 | 2015-03-31 | $4.4M | $1.7M | +59.71% |
| Q4 2014 | 2014-12-31 | $3.9M | $1.5M | +65.17% |
| Q3 2014 | 2014-09-30 | $3.1M | $1.3M | +72.25% |
| Q2 2014 | 2014-06-30 | $3.5M | $1.6M | +83.38% |
| Q1 2014 | 2014-03-31 | $2.8M | $857,069 | +44.90% |
| Q4 2013 | 2013-12-31 | $2.3M | $1.3M | +122.85% |
| Q3 2013 | 2013-09-30 | $1.8M | $24,108 | +1.34% |
| Q2 2013 | 2013-06-30 | $1.9M | $64,583 | +3.49% |
| Q1 2013 | 2013-03-31 | $1.9M | $24,843 | +1.32% |
| Q4 2012 | 2012-12-31 | $1.0M | −$1.4M | −56.46% |
| Q3 2012 | 2012-09-30 | $1.8M | −$1.6M | −46.36% |
| Q2 2012 | 2012-06-30 | $1.8M | −$4.6M | −71.37% |
| Q1 2012 | 2012-03-31 | $1.9M | −$2.0M | −51.85% |
| Q4 2011 | 2011-12-31 | $2.4M | — | — |
| Q3 2011 | 2011-09-30 | $3.4M | $987,533 | +41.71% |
| Q2 2011 | 2011-06-30 | $6.5M | $3.3M | +101.34% |
| Q1 2011 | 2011-03-31 | $3.9M | — | — |
| Q3 2010 | 2010-09-30 | $2.4M | — | — |
| Q2 2010 | 2010-06-30 | $3.2M | — | — |
Opus Genetics operating expenses trends
Over the last five fiscal years, Opus Genetics's operating expenses increased from $20.0M to $52.8M, a change of $32.8M. The latest reported quarter, Q2 2026, shows $17.2M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Opus Genetics source filings ↗